

Norske søknader mot Nanomedisin

FP7 1. call




Tor E. Johnsen
Nanomedisin i Norge, 12.12.2007

Innhold

- Evalueringss prosessen i NMP
- Enkelttema som hadde muligheter for prosjekter innen nanomedisin
- Oversikt norske søknader

NMP - Evaluation results 2007



SMALL-1

Success Rate Stage 2

Topic	Description	Main	Reserve	Total	Received	Success Rate
NMP-2007-1.1-1	Bio/non-bio interactions	9	6	15	24	63%
NMP-2007-1.1-2	Self-assembling	4	2	6	22	27%
NMP-2007-1.3-2	Nanoparticles-research	3	4	7	14	50%
NMP-2007-2.1-2	Thin films	2	5	7	17	41%
NMP-2007-2.2-2	Magnetic properties	5	2	7	10	70%
NMP-2007-2.2-3	Energy conversion	3	2	5	8	63%
NMP-2007-2.4-2	Catalysts	2	2	4	10	40%
NMP-2007-2.4-3	Packaging	1	2	3	5	60%
NMP-2007-2.5-2	Microstructure	4	2	6	17	35%
NMP-2007-3.2-1	Mechatronics	5	4	9	14	64%
NMP-2007-3.2-2	Process Intensification	3		3	6	50%
NMP-2007-3.3-1	Global Design	4		4	11	36%
NMP-2007-3.4-2	Innovative Pathways	3	2	5	11	45%
TOTAL				81	169	48%

LARGE-1

Success Rate Stage 2

Topic	Description	Received	Retained	Success Rate
NMP-2007-1.2-1	Pilot lines	6	2	33%
NMP-2007-1.3-1	Portable devices	2	1	50%
NMP-2007-2.1-1	Polymer-matrix	10	5	50%
NMP-2007-2.2-1	Organic materials	4	1	25%
NMP-2007-2.3-1	Bioactive scaffolds	6	4	67%
NMP-2007-2.5-1	Extreme conditions	8	3	38%
NMP-2007-3.1-1	Industrial Models	5	3	60%
NMP-2007-3.1-3	Risk Management	3	2	67%
NMP-2007-3.5-1	3-D Nanosurfaces	4	2	50%
NMP-2007-3.5-2	Micro-Manufacturing	9	5	56%
NMP-2007-4.0-1	Wood-Based	6	3	50%
NMP-2007-4.0-3	Vehicles	2	1	50%
NMP-2007-4.0-4	Nanomedecine	6	3	50%
NMP-2007-4.0-5	Clean Buildings	7	4	57%
TOTAL		78	39	50%

NMP – prosjekter innen Nanomedisin

Emne	Tekst	Søknader	Søknader til trinn 2	Søknader innvilget
1.1-1	Bio/non-bio interactions ¹	134	24	9
2.3-1	Bioactive scaffolds	24	7(6)	4
4.0-4	Nanomedecine	18	6	3

¹)1.1-1 inneholder mer enn nanomedisin

NMP – 1. utlysning

- **NMP-2007-1.1-1 Nano-scale mechanisms of bio/non-bio interactions**
 - 2 søknader med norske partnere, en på reserveliste, den andre avslått
- **NMP-2007-2.3.-1 Highly porous bioactive scaffolds controlling angiogenesis for tissue engineering**
 - 2 søknader med norske partnere, begge avslått
- **NMP-2007-4-4 Substantial innovation in the European medical industry: development of nanotechnology-based systems for in-vivodiagnosis and therapy**
 - 2 søknader med norske partnere, begge avslått siste runde

ICT – 1. utlysning

- **Objective ICT-2007.3.1: Next-Generation Nanoelectronics Components and Electronics Integration**
 - Ingen norske søknader som går innenfor Nanomedisin
- **Objective ICT-2007.8.1: FET proactive 1: Nano-scale ICT devices and systems**
 - Ingen norske deltakere

Health – 1. utlysning

- **HEALTH-2007-1.3-4: Alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics**
 - NanoTEST – prosjekt med NILU som koordinator – innvilget. SMALL-CP med 11 partnere, <4 mil€ i budsjett, 4 år, testmetode for nanopartikler brukt i medisin
- **HEALTH-2007-1.4-4: Development of emerging gene therapy tools and technologies for clinical application**
 - Ingen norske prosjekter

Health – 1. utlysning

- **HEALTH-2007-2.2.1-1: Stroke and mechanisms underlying ischemic brain damage**
 - 1 søknad med 3 norske partnere – avslått
- **HEALTH-2007-2.4.1-7: Improving targeted drug delivery to cancer cells for cancer therapeutics other than gene therapy**
 - 2 søknader med norske partnere – avslått
 - 1 av disse koordinert av SINTEF



Innvilget



"Reserveliste"



Avslått trinn 2

Akronym	Søkere	Prosjekt tittel
NanoTEST	NILU (koord.)	Development of methodology for alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics
NACOBIS	Rikshospitalet	Nanoscale control of biological systems
TissueReg	UiB	Tissue Engineering and Angiogenesis for Implementation in Bone Regeneration
NANO-AS	SINTEF M&K	Nanomedicine Approach to Atherosclerosis
NANOXIM	SINTEF M&K	TARGETED NANOSIZED HYBRID ORGANIC-INORGANIC X-RAY IMAGING PROBES

Avslått trinn 1

Akronym	Kortnavn	Prosjekt tittel
HNCC	St Olav Hospital	RATIONAL FOR THE EARLY INITIATION OF MILD HYPOTHERMIC NEUROCRITICAL CARE AFTER CEREBRAL ISCHEMIA.
	Stavanger Universitetshospital	
	Ullevål sykehus	
GLIOMA-TARGET	UiB	Improving targeted drug delivery to malignant glioma using antibody-based targeting approaches and local therapy
NANOSTEM	SINTEF	Emulsion based nanocarriers for targeted drug delivery to cancer stem cells
	Rikshospitalet-Radiumhospitalet	
NanoDERM	SINTEF Materialer og Kjemi	Study environmental bio-nonbio interactions to improve public safety and health
STEMBONE	SINTEF Materialer og Kjemi	Biomimetic functionalised scaffolds for bone and nerve tissue engineering